Authors :
Taher Ibrahim; Ebrahim Souliman; Basem Maarof
Volume/Issue :
Volume 7 - 2022, Issue 10 - October
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3UT5gFC
DOI :
https://doi.org/10.5281/zenodo.7316055
Abstract :
Background: Renin-angiotensin system
blockers (ACE-I or ARBS) is well known to be associated
with hyperkalemia in patients with advanced chronic
kidney disease (CKD) who are not on dialysis. However,
few studies have investigated the relationship between
renin-angiotensin system blockers (RASB) and
hyperkalemia in chronic HD patients, and the results
remain controversial. Methods: The research sample
included 111 patients from hemodialysis patients in the
hemodialysis division at Tishreen University Hospital in
Latakia,Syria .The research sample was divided into two
groups : the first group takes RASB and the second
group was not taking these medications in order to study
the effect of these medication on serum potassium levels
.A blood potassium analysis was conducted monthly for
6 months during the time period 2019-2020. Resuls:
there was no statistically significant difference in the
mean values of serum potassium between the two
research groups , but it was lower in the case
group.Where the mean values of serum potassium were
between the group that was taking RASB and the group
Keywords :
Renin-Angiotensin System Blockers , Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Receptor Blocker, Hyperkalemia , Hemodialysis.
Background: Renin-angiotensin system
blockers (ACE-I or ARBS) is well known to be associated
with hyperkalemia in patients with advanced chronic
kidney disease (CKD) who are not on dialysis. However,
few studies have investigated the relationship between
renin-angiotensin system blockers (RASB) and
hyperkalemia in chronic HD patients, and the results
remain controversial. Methods: The research sample
included 111 patients from hemodialysis patients in the
hemodialysis division at Tishreen University Hospital in
Latakia,Syria .The research sample was divided into two
groups : the first group takes RASB and the second
group was not taking these medications in order to study
the effect of these medication on serum potassium levels
.A blood potassium analysis was conducted monthly for
6 months during the time period 2019-2020. Resuls:
there was no statistically significant difference in the
mean values of serum potassium between the two
research groups , but it was lower in the case
group.Where the mean values of serum potassium were
between the group that was taking RASB and the group
Keywords :
Renin-Angiotensin System Blockers , Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Receptor Blocker, Hyperkalemia , Hemodialysis.
